Natera
Trade Natera 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About NTRA
Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT).
NTRA Key Statistics
Stock Snapshot
The current Natera(NTRA) stock price is $289.92, with a market capitalization of 42.04B. The stock trades at a price-to-earnings (P/E) ratio of -252.55.
On 2026-11-19, Natera(NTRA) stock traded between a low of $288.20 and a high of $307.19. Shares are currently priced at $289.92, which is +0.6% above the low and -5.6% below the high.
Natera(NTRA) shares are trading with a volume of 2.31M, against a daily average of 2.5M.
During the past year, Natera(NTRA) stock moved between $181.00 at its lowest and $437.41 at its peak.
During the past year, Natera(NTRA) stock moved between $181.00 at its lowest and $437.41 at its peak.
NTRA News
Free Article Explore Premium Services Natera vs. Tempus AI: Which Blood Test Pioneer Has the Better Stock Buy for 2027? Natera's revenue growth tops 37%, but Te...
Piper Sandler lowered the firm’s price target on Natera (NTRA) to $350 from $363.50 following quarterly results. The firm keeps an Overweight rating on the shar...
Natera (NTRA) has moved into focus after its CFO outlined a multi year revenue plan centered on the Signatera cancer testing franchise, tying that roadmap to re...
Analyst ratings
88%
of 24 ratingsMore NTRA News
Natera Inc. ((NTRA)) has held its Q3 earnings call. Read on for the main highlights of the call. Natera delivered a strongly positive quarter, marked by record...
On CNBC’s “Halftime Report Final Trades,” Bill Baruch, founder and CIO of both Blue Line Capital and Blue Creek Capital Management, picked Micron Technology, In...
Natera (NasdaqGS:NTRA) and Incyte announced a clinical collaboration using Signatera in a Phase II colorectal cancer immunotherapy trial. The study will use Si...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.